Last reviewed · How we verify
Unfractionated Heparin IV
Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute coronary syndrome (unstable angina and myocardial infarction), Pulmonary embolism treatment and prevention, Deep vein thrombosis treatment and prevention.
At a glance
| Generic name | Unfractionated Heparin IV |
|---|---|
| Sponsor | The TIMI Study Group |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); indirect inhibitor of thrombin and Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically accelerates its inhibition of thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the propagation of existing thrombi. UFH has a rapid onset of action when administered intravenously, making it suitable for acute anticoagulation in time-sensitive clinical scenarios.
Approved indications
- Acute coronary syndrome (unstable angina and myocardial infarction)
- Pulmonary embolism treatment and prevention
- Deep vein thrombosis treatment and prevention
- Atrial fibrillation with thromboembolism risk
- Cardiopulmonary bypass anticoagulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis (paradoxical, in HIT)
- Osteoporosis (with prolonged use)
- Hyperkalemia
Key clinical trials
- Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (PHASE4)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients (PHASE4)
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (PHASE1)
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Unfractionated Heparin IV CI brief — competitive landscape report
- Unfractionated Heparin IV updates RSS · CI watch RSS
- The TIMI Study Group portfolio CI